RadTag multimodal bioimaging
| Reference number | |
| Coordinator | Linköpings universitet - Institutionen för medicin och hälsa |
| Funding from Vinnova | SEK 1 642 000 |
| Project duration | November 2012 - June 2015 |
| Status | Completed |
Purpose and goal
The use of biologicals in molecular imaging is hampered due to the lack of appropriate nuclear medical labeling technology. We have developed a new chemical series, RadTag for nuclear medical labeling of biologicals. The aim of the project was to validate our innovation from a technical and commercial point of view. Our results show that RadTag has a great commercial potential. The technical studies have given evidence to further support applications within molecular imaging.
Expected results and effects
RadTag can be used to radiolabel biologicals using standard nuclear medical technology, without affecting primary pharmacological properties of the target molecule. In preclinical studies, we have shown the possibility to image melanoma tumors in mice, by using RadTag label MSH peptides, that binds to the surface of tumor cells. Regulatory pathway for this clinical application have been mapped and the requirement for this type of product is much more limited than for therapeutic molecules.
Planned approach and implementation
Technical validation of the methodology has been done in collaboration with the Dept of Chemistry Linköping University, Novandi Chemistry, University of Arizona, the PET Center at Dept of Clinical Neuroscience, Karolinska Institutet and AstraZeneca Translational Science KI. Our efforts have focused on radiochemical synthesis and in vitro and in vivo performance. Mapping of commercial potential, and regulatory requirements for clinical applications have been made in collaboration with leading experts from Swedish biotech and AS-Tec Chemicals.